ArticleAMB Express2026
Atmospheric room-temperature plasma mutagenesis and heterologous expression of dextranase in Aspergillus niger.
Article in AMB Express, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 1 paper.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
1 citing paper in PubMed.
- Screening and ARTP mutagenesis-based breeding of high-cellulase-producing strains.Brazilian journal of microbiology : [publication of the Brazilian Society for Microbiology] · 2026Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
8 authors.
Funding
Abstract
Dextranase (DEX) is a high-value biocatalyst with substantial potential in oral hygiene and diverse industrial bioprocesses, yet its practical application is frequently constrained by the insufficient yields of wild-type strains. In this study, a high-efficiency DEX production system was established through an integrated strategy comprising Atmospheric and Room Temperature Plasma (ARTP) mutagenesis, molecular mechanism elucidation, and host-specific promoter engineering. A stable mutant, Chaetomium gracile B12, was isolated, exhibiting a 30.6-fold increase in DEX activity (16.23 U/mL) compared to the parental strain. Sequence analysis and multi-scale computational simulations, including AlphaFold2-based modeling and 100 ns molecular dynamics, generated a testable hypothesis that this mutation may contribute this enhancement. This substitution was found to augment structural rigidity and refine the spatial orientation of the substrate within the active pocket, facilitating a more "productive alignment" for catalysis. Furthermore, heterologous expression optimization uncovered a distinct host-specific promoter preference: the heterologous Pcdna1 promoter was most effective in C. gracile, whereas the endogenous inducible PgpdA proved superior in Aspergillus niger. Notably, this pioneering heterologous expression of DEX in A. niger streamlined the production cycle, slashing the fermentation period from 6 days to 48 h. Following systematic optimization of carbon/nitrogen sources and aeration intensity, the engineered A. niger strain H achieved a peak DEX activity of 36.00 U/mL. Biochemical characterization revealed that the recombinant DEX possessed a favorable near-neutral optimal pH (6.0-7.0) and a temperature optimum of 50 °C. Overall, this study reports the first heterologous expression of a dextranase in A. niger, reducing the fermentation period from 6 days to 48 h, and provides a comprehensive strategy for the overproduction of dextranase and offers molecular insights into enzymatic "fine-tuning", yielding a high-titer, neutral-pH compatible biocatalyst with significant promise for oral care and industrial applications.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.